Pila Pharma wins EMA approval for 12-week obesity trial of XEN-D0501
Reuters2026/08/18 09:33Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Pila Pharma secured EMA clearance to run PP-CT04, a 12-week Phase II trial of XEN-D0501 in obesity.
- Study to assess safety, tolerability, pharmacokinetics, efficacy; dose titration from 4 mg twice daily up to 16 mg twice daily.
- Trial plans 46 participants across two parts, starting with an 8-person pilot safety cohort before expansion.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Foreign media: ATOM rebound is hindered, price falls back to around $1.41
币界网•2026/08/18 18:41
Wabtec EVP Operations Gregory Sbrocco sells 952 common shares for $285,600
Reuters•2026/08/18 18:37
Weave Communications Up Over 31%, on Track for Record Percent Increase -- Data Talk
Dow Jones•2026/08/18 18:32
